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Borderline Personality Disorder is a mood disorder characterized by emotional 
dysregulation, increased impulsivity, and increased self-harm. Recently, a positive 
correlation has been made relating number of body modifications (such as piercings, 
tattoos, and scarification) and severity of disease. Dialectical Behavior Therapy is the 
first-line treatment for Borderline Personality Disorder and has been found to 
significantly reduce engagement in another form of self-harming behavior (non-suicidal 
self-injury). However, the effects of Dialectical Behavior Therapy on body modification 
are not understood. In this randomized control study, we will compare the effects of 
Dialectical Behavior Therapy, pharmacotherapy, or non-treatment on the number 
of body modifications in participants with untreated Borderline Personality 
Disorder. Additionally, fMRI data will be obtained to better understand the neural 
mechanisms underlying engagement in body modification. This study will allow 
providers to better understand, recognize, and treat individuals with Borderline 
Personality Disorder who engage in frequent body modification.
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CHAPTER 1: INTRODUCTION 
1.1 BACKGROUND 
Borderline Personality Disorder (BPD) is a mood disorder characterized by a 
pervasive pattern of instability in an individual’s interpersonal relationships, personal 
identity, impulsivity, and affect.1-3 These characteristics are further outlined by the DSM-
V Diagnostic Criteria for BPD (Table 1), of which an individual must meet five out of 
nine criteria in order to be diagnosed.3 When studied in the general United States 
population, epidemiologic studies suggest that the prevalence of BPD has a broad range, 
occurring in anywhere from 0.5%-5.9% of the population with a median prevalence of 
1.35%.4-6 Yet when studied in a clinical setting, this prevalence increases to 15-25%, 
demonstrating that a large portion of the population goes undiagnosed and thus 
untreated.7 
Table 1. DSM-V Diagnostic Criteria for Borderline Personality Disorder 
A pervasive pattern of instability of interpersonal relationships, self-image, and affects, 
and marked impulsivity beginning by early adulthood and present in a variety of 
contexts, as indicated by five (or more) of the following:  
1. Frantic efforts to avoid real or imagined abandonment. (Note: Do not include 
suicidal or self-mutilating behavior covered in Criterion 5.) 
2. A pattern of unstable and intense interpersonal relationships characterized by 
alternating between extremes of idealization and devaluation.  
3. Identity disturbance: markedly and persistently unstable self-image or sense of 
self. 
4. Impulsivity in at least two areas that are potentially self-damaging (e.g., 
spending, sex, substance misuse, reckless driving, binge eating). (Note: Do not 
include suicidal or self-mutilating behavior covered in Criterion 5.) 
5. Recurrent suicidal behavior, gestures, or threats, or self-mutilating behavior. 
6. Affective instability due to a marked reactivity of mood (e.g., intense episodic 
dysphoria, irritability, or anxiety usually lasting a few hours and only rarely 
more than a few days). 
7. Chronic feelings of emptiness. 
8. Inappropriate, intense anger or difficulty controlling anger (e.g., frequent 
displays of temper, constant anger, recurrent physical fights). 
9. Transient, stress-related paranoid ideation or severe dissociative symptoms. 
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Source: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, 2013, 
American Psychiatric Association. 
Even though BPD is underdiagnosed in the United States, a substantial amount of 
research has been conducted to identify the most efficacious treatment options for 
patients who are ultimately diagnosed with BPD. Current evidence does not support the 
use of pharmacotherapy alone in BPD, but the use of pharmacotherapy to target specific 
BPD symptoms such as affective dysregulation, impulsive-behavioral dysregulation, 
paranoia, or dissociation has been shown to be effective.1 For example, Selective 
Serotonin Reuptake Inhibitors (SSRIs) such as fluoxetine, sertraline, and venlafaxine 
have been found to decrease affective dysregulation and impulsive-behavioral 
dysregulation, while neuroleptics such as haloperidol have demonstrated effectiveness in 
managing symptoms of behavioral dysregulation, paranoia, and dissociation.1   
Rather than pharmacotherapy alone, the current first-line treatment for BPD is 
psychotherapy. Dialectical Behavior Therapy (DBT), a form of psychotherapy developed 
by Dr. Marsha Linehan in the 1990s, has the most evidence for the treatment of BPD.1,2,8 
DBT involves four components: a weekly skills training group, a weekly hour-long 
individual psychotherapy session, telephone consultation between sessions as needed, 
and a weekly therapist consultation team meeting.8 Most trials evaluating the efficacy of 
DBT in the treatment of BPD have been 12 months in duration, though studies are 
underway to evaluate the efficacy of six-month programs as an alternative for patients.9 
Ultimately, the goal of DBT is to allow for people with BPD to be able to self-recognize 
maladaptive behavior, and then apply both problem-oriented and supportive techniques to 
better manage their behavior.8,10  
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 One kind of maladaptive behavior is described in criterion 5 of the DSM-V 
criteria for the diagnosis of BPD: the engagement in recurrent suicidal gestures, or 
threats, or non-suicidal self-injury (NSSI) such as skin cutting, scraping, scratching, 
burning, or scarring.3 It has been hypothesized that recurrent self-harm in BPD may be 
due to altered pain perception. In experimental paradigms where individuals with BPD 
were exposed to painful physical stimuli, researchers not only found a generalized 
reduction of pain perception in the group of participants with BPD, but they also found 
that those who engaged in either NSSI or indirect self-injury demonstrated an increased 
pain threshold and endurance compared to healthy control participants.11,12 Functional 
magnetic resonance imaging (fMRI) has been used to extend these behavioral findings to 
understand the underlying neural mechanisms. In one such study, patients with BPD 
demonstrated an increased response in the dorsolateral prefrontal cortex (dlPFC) and 
deactivation in the anterior cingulate and amygdala when exposed to painful thermal 
stimuli.13 
In addition to understanding the behavioral and neural mechanisms of NSSI, it is 
important to consider the ways in which it may be possible to treat or reduce engagement 
in these self-harming behaviors. A recent study has aimed to better understand the effects 
of 12 weeks of DBT compared to treatment as usual in a group of people with BPD who 
engaged in frequent NSSI.14 In this study, treatment as usual was defined as non-DBT 
treatment that participants were participating in prior to study initiation (outpatient 
psychotherapy, residential crisis intervention, pharmacotherapy, self-help, and non-
specific community-based treatment).14 While there was no significant change in pain 
threshold identified following 12 weeks of DBT, it did appear that there were significant 
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changes in neural mechanisms. When analyzing the amygdala, these researchers found a 
neural deactivation in response to painful stimuli at baseline, which was no longer present 
in participants who received treatment with DBT.14 This research suggests that DBT may 
alter the neural mechanisms underlying pain response, as well as reduce engagement in 
NSSI.15  
To this point, most research has focused primarily on either suicidal behavior or 
NSSI, with little insight into a subset of different behaviors deemed “body modification.” 
Body modification is defined as “the process of purposefully altering previously 
unaltered parts of the body”16 and may include engagement in activities such as piercings, 
tattooing, scarification, pubic hair removal, or cosmetic surgery.17 Specific body 
modifications, such as tattooing, have been found to be associated with a diagnosis of 
personality disorder, yet were previously only anecdotally related to BPD specifically.18 
More recently, the number of BPD features or severity of disease and total number of 
body modifications have been positively correlated.17 Given the dearth of research within 
this area of BPD, there lacks a firm understanding of the etiology or neural circuitry 
underlying this relationship. Further research is needed to identify if individuals with 
BPD who engage in frequent body modification demonstrate an increased pain threshold 
and endurance like those who engage in frequent NSSI. Additionally, while it is 
understood that DBT can be utilized to reduce a patient’s engagement in suicidal 
behaviors or NSSI,15,19-22 we do not know the effect of DBT on engagement in body 
modification in patients with BPD. Ultimately, while body modification does not appear 
to be inherently harmful as is NSSI or suicidal behavior, researchers do not yet have a 
firm understanding of the motivation for, underlying neural mechanisms of, and effects of 
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treatment on body modification in people with BPD. This information will be an 
important diagnostic and prognostic tool for clinicians to utilize when treating individuals 
with BPD.  
1.2 STATEMENT OF THE PROBLEM 
The effect of DBT on engagement in body modification as well as the underlying 
neural mechanisms of pain response in people with BPD, has not yet been adequately 
studied. It is worthwhile to explore this topic so that providers can gain a better 
understanding as to whether the treatment modality recommended for suicidal behavior 
and NSSI, is also beneficial for patients engaging in frequent body modification or if it 
modifies their engagement in body modification. Additionally, by further understanding 
the possible relationship between pain response and engagement in body modification, 
providers will be better equipped to discuss the etiology of this behavior with their 
patients. 
1.3 GOALS AND OBJECTIVES 
This randomized controlled trial (RCT) serves to look at the effects of 12 weeks 
of DBT compared to pharmacotherapy alone or no treatment on the mean number of 
body modifications and pain response in patients with previously untreated BPD. Patients 
diagnosed with BPD who have engaged in body modification frequently within the past 
six months and who are not currently receiving BPD-directed therapy (either 
pharmacotherapy or behavioral therapy such as DBT) will be recruited for this study. 
Baseline measurements of number of body modifications will be obtained using the Body 
Modification Questionnaire (BMQ), as well as pain tolerance as measured by QST, and 
neural response as measured by fMRI. Participants will be randomized into one of three 
6 
 
groups: DBT, pharmacotherapy, and non-treatment. DBT will be provided by a single 
post-doctoral student and pharmacotherapy will be prescribed by the site’s Principal 
Investigator (PI), Dr. Fineberg. Following 12 weeks, the baseline measurements will be 
repeated to evaluate the effects of the randomized intervention. 
1.4 HYPOTHESIS 
Among adults diagnosed with BPD there will be a significant reduction in mean 
number of body modifications following completion of 12 weeks of Dialectical Behavior 
Therapy compared to groups randomized to pharmacotherapy or no treatment.   
1.5 DEFINITIONS 
Body Modification: process of purposefully altering previously unaltered parts of the 
body and may include engagement in activities such as piercings, tattooing, scarification, 
pubic hair removal, or cosmetic surgery. 
Dialectical Behavior Therapy (DBT): a form of psychotherapy developed in the 1990s 






1. American Psychiatric Association practice guidelines. 1st ed. Washington, DC: 
The Association; 1996. 
2. Chanen AM, Thompson KN. Prescribing and borderline personality disorder. Aust 
Prescr. 2016;39(2):49-53. 
3. Association AP. Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition. 5 ed. Arlington, VA: American Psychiatric Association; 2013. 
4. Torgersen S, Kringlen E, Cramer V. The prevalence of personality disorders in a 
community sample. Arch Gen Psychiatry. 2001;58(6):590-596. 
5. Lenzenweger MF, Lane MC, Loranger AW, Kessler RC. DSM-IV personality 
disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 
2007;62(6):553-564. 
6. Grant BF, Chou SP, Goldstein RB, et al. Prevalence, correlates, disability, and 
comorbidity of DSM-IV borderline personality disorder: results from the Wave 2 
National Epidemiologic Survey on Alcohol and Related Conditions. J Clin 
Psychiatry. 2008;69(4):533-545. 
7. Gunderson JG. Borderline personality disorder: ontogeny of a diagnosis. Am J 
Psychiatry. 2009;166(5):530-539. 
8. May JM, Richardi TM, Barth KS. Dialectical behavior therapy as treatment for 
borderline personality disorder. Ment Health Clin. 2016;6(2):62-67. 
9. McMain SF, Chapman AL, Kuo JR, et al. The effectiveness of 6 versus 12-
months of dialectical behaviour therapy for borderline personality disorder: the 
feasibility of a shorter treatment and evaluating responses (FASTER) trial 
protocol. BMC Psychiatry. 2018;18(1):230. 
10. Linehan MM, Armstrong HE, Suarez A, Allmon D, Heard HL. Cognitive-
behavioral treatment of chronically parasuicidal borderline patients. Arch Gen 
Psychiatry. 1991;48(12):1060-1064. 
11. St Germain SA, Hooley JM. Aberrant pain perception in direct and indirect non-
suicidal self-injury: an empirical test of Joiner's interpersonal theory. Compr 
Psychiatry. 2013;54(6):694-701. 
12. Hooley JM, Ho DT, Slater J, Lockshin A. Pain perception and nonsuicidal self-
injury: a laboratory investigation. Personal Disord. 2010;1(3):170-179. 
13. Schmahl C, Bohus M, Esposito F, et al. Neural correlates of antinociception in 
borderline personality disorder. Arch Gen Psychiatry. 2006;63(6):659-667. 
14. Niedtfeld I, Schmitt R, Winter D, Bohus M, Schmahl C, Herpertz SC. Pain-
mediated affect regulation is reduced after dialectical behavior therapy in 
borderline personality disorder: a longitudinal fMRI study. Soc Cogn Affect 
Neurosci. 2017;12(5):739-747. 
15. Storebo OJ, Stoffers-Winterling JM, Vollm BA, et al. Psychological therapies for 
people with borderline personality disorder. Cochrane Database Syst Rev. 
2020;5:CD012955. 
16. Bercaw-Pratt JL, Santos XM, Sanchez J, Ayensu-Coker L, Nebgen DR, Dietrich 
JE. The incidence, attitudes and practices of the removal of pubic hair as a body 
modification. J Pediatr Adolesc Gynecol. 2012;25(1):12-14. 
8 
 
17. Vizgaitis AL, Lenzenweger MF. Pierced identities: Body modification, borderline 
personality features, identity, and self-concept disturbances. Personal Disord. 
2019;10(2):154-162. 
18. Buhrich N, Morris G. Significance of tattoos in male psychiatric patients. Aust N 
Z J Psychiatry. 1982;16(3):185-189. 
19. Pasieczny N, Connor J. The effectiveness of dialectical behaviour therapy in 
routine public mental health settings: An Australian controlled trial. Behav Res 
Ther. 2011;49(1):4-10. 
20. Stanley B, Brodsky B, Nelson JD, Dulit R. Brief dialectical behavior therapy 
(DBT-B) for suicidal behavior and non-suicidal self injury. Arch Suicide Res. 
2007;11(4):337-341. 
21. Linehan MM, Korslund KE, Harned MS, et al. Dialectical behavior therapy for 
high suicide risk in individuals with borderline personality disorder: a randomized 
clinical trial and component analysis. JAMA Psychiatry. 2015;72(5):475-482. 
22. Bohus M, Haaf B, Simms T, et al. Effectiveness of inpatient dialectical behavioral 







Chapter 2 – Review of the Literature 
2.1 INTRODUCTION 
 An exhaustive literature search was conducted between July 2020 and August 
2021 using Ovid, MEDLINE, PubMed, Scopus, APA PsycBooks, and APAPsycExtra. 
Terminology used in the primary literature search included “Borderline Personality 
Disorder” OR “DBT” AND “body modification” OR “tattoo” OR “body piercing” OR 
“scarification”. Additional search terms included “Dialectical Behavior Therapy”, 
“DBT”, “pain”, “pain processing”, “pain threshold”, “pain response”, “pain adaptation”, 
“altered pain response”, “fMRI”, “functional magnetic resonance imaging”, “magnetic 
resonance imaging”, “trauma”, “NSSI”, “non-suicidal self-injury”, “childhood abuse”, 
“childhood trauma”, “quantitative sensory testing”, “method of limits”, “age”, and 
“impulsivity”. Studies were deemed relevant based on their title and subsequent review 
of their abstracts. The full article for each relevant study was obtained, reviewed, and if 
relevance remained, were included in this study’s literature review. Additional resources 
and studies were obtained by utilizing those referenced in sources already deemed 
relevant to this study. The studies included in this literature review were those with a 
study population of individuals between the ages 11-65 years old and participants 
diagnosed with either a personality disorder or borderline personality disorder. The 
designs of studies included were randomized control trials, non-randomized trials, meta-
analyses, systematic reviews, and case reports.  
2.2 REVIEW OF EMPIRICAL STUDIES ABOUT THE RELATIONSHIP BEING 
STUDIED  
2.2.1 DBT as the first-line treatment for BPD 
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DBT was first developed by Dr. Linehan in the 1990’s to treat people with BPD.1 
It is based on cognitive behavioral therapy and utilizes multiple components in order to 
help individuals better manage emotional, behavioral, and interpersonal dysfunction. 
DBT typically consists of one year of weekly skills training groups, weekly hour-long 
individual psychotherapy sessions, telephone consultation between sessions as needed, 
and weekly therapist consultation team meetings.2 More specifically, the skills training 
group aims to make people with BPD aware of common behavioral skill deficits related 
to self-identity, interpersonal relationships, emotion control and awareness, thoughts of 
abandonment, and impulsivity.2 It then uses training modules in four key areas (core 
mindfulness, interpersonal effectiveness, emotion regulation, and distress tolerance) to 
teach these individuals to recognize maladaptive thoughts or actions and to learn new 
non-maladaptive, more effective coping methods to respond.2 
A great deal of research has been conducted to identify the effectiveness of DBT 
in reducing severity of BPD symptoms and engagement in suicidal behavior or NSSI. 
One of the first studies conducted was by Dr. Linehan in 1991, and it compared the 
effects of DBT to no treatment in parasuicidal people with BPD.3 Parasuicidal behavior 
was defined in this study as “any intentional, acute self-injurious behavior with or 
without suicidal intent, including both suicide attempts and self-mutilative behaviors.”3 
This study found that there was a significant decrease in the engagement in parasuicidal 
behavior in individuals that were randomized to the DBT arm compared to no treatment.3 
There have been numerous studies since these initial investigations that have provided 
empiric evidence supporting the efficacy of DBT in the treatment of BPD.4-9 Most 
recently, a meta-analysis was completed to assess the effects of various psychological 
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therapies in people diagnosed with BPD.4 Included in the review were RCTs which 
compared a variety of psychotherapy modalities, primarily DBT and mentalization-based 
treatment (MBT) to treatment as usual (either community treatment or any treatment 
which was not the experimental treatment being studied) or a waiting list. Findings from 
this analysis revealed that “DBT was more effective at reducing BPD severity, self-harm, 
and improving psychosocial functioning,”4 than other forms of treatment. This evidence 
has provided the framework for the American Psychiatric Committee Practice 
Guidelines, which currently recommend psychotherapy as the first-line treatment for 
BPD.10 
2.2.2 Non-suicidal self-injury (NSSI) in individuals with BPD 
The DSM-V outlines the diagnostic criteria for BPD (Table 1); patients must meet 
five of nine criteria to receive a diagnosis of BPD. Criterion five describes engagement in 
recurrent suicidal gestures or threats, or self-mutilating behavior such as NSSI or body 
modification. NSSI can include behaviors such as cutting, burning, scratching, self-
hitting, head banging, bone breaking, hair pulling, nail biting that results in bleeding, or 
interfering with wound healing.11 Engagement in NSSI occurs in a higher percentage of 
people with BPD12 and has a prevalence from around 4-5.9% of the general adult US 
population.11 Many studies have found that prior to NSSI, individuals typically endorse 
negative feelings or emotions such as sadness and frustration, but that there is a 
significant improvement in these emotions following completion of NSSI.13-16 This data 
suggests that NSSI serves as a method for people with BPD to achieve immediate relief 
from stressors and negative emotions. 
2.2.3 Body modification in patients with BPD 
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Unlike NSSI, little research has been conducted to better understand a subset of 
self-mutilating behavior considered under criterion five of the DSM-V diagnostic criteria 
for BPD known as “body modification.” As previously discussed, body modification is 
the process of purposefully altering the body through either permanent or non-permanent 
methods such as piercing, tattooing, scarification, pubic hair removal, or cosmetic 
surgery.17,18 While other non-painful and non-permanent methods of body modification 
(wearing thick makeup) have been found to be related to BPD,19 this paper will focus 
primarily on painful and permanent body modifications.  
Prior research has demonstrated a correlation between body modification and 
different forms of psychological and personality disorders.20-24 Since this relationship was 
demonstrated, physicians and researchers have anecdotally reported a positive correlation 
between BPD specifically and repeated engagement in forms of body modification such 
as piercing and tattooing.25,26 These claims have been further supported by research 
conducted by Manuel and Retzlaff who studied the relationship between 
psychopathology and tattooing in 8,574 prison inmates.27 These researchers found a 
significant correlation between BPD pathology and engagement in tattooing.27 More 
recently, researchers have demonstrated a statistically significant correlation between the 
total number of body modifications a person engages in and the number of BPD features 
that they demonstrate.17 This research demonstrates that like NSSI and suicidal behavior, 
there is likely a relationship between engagement in body modification and diagnosis of 
BPD. However, unlike NSSI and suicidal behavior, there is no research to date 
demonstrating if DBT has any effect on further engagement in body modification or if 
body modification leads to relief of negative stressors or emotions.   
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2.2.4 Altered pain response in patients with BPD 
As researchers have gathered evidence supporting the relationship between BPD 
and engagement in suicidal behavior, NSSI, and body modification, they have also begun 
to research the etiology of this behavior. Prior studies have demonstrated that 
engagement in such behavior may likely be related to a key feature of BPD: 
hyposensitivity to pain.28 This concept has been further studied through the application of 
painful stimulation using various modalities, which include the following: thermal stimuli 
(Cold Pressor Test or other methods of applying heat stimuli),29-36 tactile or mechanical 
stimuli (Tourniquet Pain Test, small incisions, or electrical stimulation via probes),31,37-41 
or injections.38 When utilizing these modalities in order to elicit a pain response in 
participants, these studies have consistently found that compared to healthy control 
participants, individuals with BPD report decreased pain ratings,30-35,37,38 demonstrate an 
increased pain threshold (point which onset of pain is reported),30,31,34,35,38-41 are able to 
adapt to pain faster,29 and tend to demonstrate a higher level of tolerance for pain (point 
at which participants physically withdraw from a painful stimulus).42 Additional research 
has demonstrated that this reduction in response to and perception of painful stimuli in 
people with BPD is further reduced during periods of increased stress.31,39 In sum, this 
data allows researchers to conjecture that there may be a relationship between these 
decreased pain thresholds and increased pain tolerance, and engagement in potentially 
painful behaviors such as NSSI or body modification.  
2.2.5 Functional magnetic resonance imaging (fMRI) to evaluate alterations in 
pain processing in patients with BPD 
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While it is established that people with BPD report an increased pain 
threshold30,31,34,35,38-41 and greater tolerance for pain,42 it is important to understand the 
underlying neural processing of pain and how this may differ in BPD. Researchers have 
combined fMRI with various methods intended to cause physical or imagined pain in 
order to evaluate the underlying pathways and structures involved in pain processing in 
healthy control subjects. These studies have revealed that there is significant activation in 
both the anterior cingulate cortex (ACC),43,44 dorsolateral prefrontal cortex (dlPFC),45 
primary and secondary somatosensory cortex, and anterior and posterior insula.46   
Prior research has helped to elucidate the potential roles which these brain regions 
may play in processing information. Research conducted by Sakagami and Watanabe, 
suggests that the dlPFC is responsible for integrating “cognitive and motivational context 
to enable adaptive goal-directed behavior.” 47 Yet while integrating information to guide 
behavior is one role of the dlPFC, it serves several additional functions such as adaptive 
decision making, action planning, and self-control.48,49 A systematic review completed by 
Apkarian, Bushnell, Treede, and Zubieta provides evidence that the primary and 
secondary somatosensory cortexes, insular cortex, and ACC are activated in response to 
both physical painful stimuli and emotional pain.50  
Schmahl, Bohus, Esposito, et al evaluated how the neural processing of pain may 
differ in a group of individuals with BPD.35 They accomplished this through a case-
control study in which they recruited 12 females diagnosed with BPD and 12 healthy age-
matched female controls.35 These participants were exposed to heat stimuli using a TSA-
II sensory tester and underwent an fMRI scan using a 1.5 Tesla MRI scanner. Image 
analysis demonstrated that when comparing participants with BPD to healthy controls, 
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there was a significant difference in activity in the dlPFC, posterior parietal cortex (PPC), 
ACC, and amygdala.35 More specifically, participants with BPD demonstrated lower 
activity in the right PPC and increased activity in the left dlPFC during the early phase of 
temperature stimulation.35 During the late phase of temperature stimulation, there was 
less activity in the perigenual region of the ACC, left temporal pole, and right 
amygdala.35 This study demonstrates that when exposed to painful stimuli, there is 
increased activity in the left dlPFC and decreased activity in the ACC in people with 
BPD compared to healthy control participants.  
While additional research is required in order to provide more than just 
speculation, it is important to consider what alterations in these specific brain regions 
may mean or how they may contribute to BPD symptomatology. Prior research has 
demonstrated that increased connectivity between the ventral striatum and dlPFC during 
reward conditions serves to reinforce behavior.51 Meanwhile, Schmahl, Bohus, Esposito, 
et al. demonstrate an increase in dlPFC activity during the early stages of painful stimuli 
in participants with BPD.35 Taking both findings together may suggest a mechanism of 
positive reinforcement mediated by the enhanced connectivity between the ventral 
striatum and the dlPFC and subsequent activation of dlPFC in response to painful stimuli. 
This may help to explain why people with BPD continue to engage in behavior which 
elicits a similar pain response.  
Additionally, Schmahl, Bohus, Esposito, et al. found there to be decreased activity 
in the ACC during the late stage of temperature stimulation in participants with BPD 
compared to healthy control participants.35 Given the role of the ACC in processing both 
physical and emotional pain,50 this finding may suggest a modified pain response in 
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people with BPD such that they are able to acclimate to pain faster. While this is one 
possible explanation, one could imagine that this may also be demonstrative of an altered 
pain response like that found in patients with chronic or clinical pain conditions. The 
Apkarian, Bushnell, Treede, and Zubieta meta-analysis found data to suggest a decreased 
activation of the primary and secondary somatosensory cortexes, insular cortex, and ACC 
during noxious stimuli in participants with a clinical pain condition compared to normal 
participants.50 When considering these findings, one could speculate that people with 
BPD may repeatedly engage in painful behavior due to changes in the neural mechanisms 
responsible for processing pain, like that seen in chronic pain conditions. 
2.2.6 Effects of DBT on pain sensitivity and pain processing 
It is understood that DBT is the first-line treatment for BPD symptomatology 
(including engagement in NSSI and suicidal behavior)10 and that individuals with BPD 
demonstrate alterations in brain activation in response to painful stimuli,35 but recent 
studies have been conducted in order to learn more about the relationship between these 
variables. Niedtfeld, et al. compared participants with BPD receiving DBT treatment, 
participants with BPD receiving treatment as usual, and healthy control participants in 
order to further understand the effects of DBT on pain sensitivity and the “affect-
regulating function of pain.”52 All BPD participants met DSM-IV criteria for BPD, and 
all engaged in frequent NSSI during the six months prior to study participation. This 
study included two fMRI scans separated by 12 weeks during which participants were 
subjected to both photos and temperature stimuli. This study found that like prior studies, 
there is a deactivation of the amygdala in response to painful stimuli, but that this was no 
longer present after 12 weeks, in patients enrolled in DBT.52 Additionally, Niedtfeld, et 
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al. found that individuals with BPD demonstrated a decreased sensitivity to painful 
stimuli, but that this was not normalized following DBT.52 In sum, these researchers were 
able to reproduce prior findings of reduced sensitivity to pain in people with BPD and the 
ability of DBT to normalize pain-mediated affect regulation, but were unable to provide 
evidence that DBT has an effect on altering pain sensitivity in BPD.52   
2.3 REVIEW OF STUDIES TO IDENTIFY POSSIBLE CONFOUNDING 
VARIABLES 
The first confounding variable to be controlled for is medical history. This study 
will exclude participants with the following conditions: any serious medical or 
neurological illness, traumatic brain injury, schizophrenia, bipolar (Type I) disorder, 
current Major Depressive Disorder (MDD) within the past 6 months, developmental 
disorders such as Attention Deficit Disorder (ADD) or Attention Deficit Hyperactive 
Disorder (ADHD), chronic pain disorder, peripheral neuropathy, loss of consciousness, or 
a substance use disorder. It is important to control for these diagnoses for several reasons 
as outlined by the DSM-5.53 Serious medical or neurological illnesses can lead to 
personality changes, some developmental conditions (ADD or ADHD) can lead to 
challenges with identity, and individuals with a substance use disorder or episodes of 
MDD and bipolar disorder can have in-the-moment behavior almost identical to that of 
BPD.53 These conditions have the possibility to confound this study’s sample size and 
inadvertently allow for the recruitment of patients with diagnoses other than BPD, 
making it important to exclude these conditions. 
 A second variable which will be controlled for is medication use. This study will 
control for medications by excluding the following: chronic NSAID use, opioids, opioid 
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replacement therapy (such as methadone, suboxone, buprenorphine, or naltrexone), 
topiramate, lamotrigine, lithium, benzodiazepines, and muscle relaxants. More 
specifically, because this study is looking at pain tolerance and endurance, potential 
participants who engage in chronic NSAID use (daily use for greater than one year) will 
be excluded.54  
A third category of possible confounding variables for which will be controlled 
for includes demographics such as age, sex, race, and education. Prior research conducted 
by Vizgaitis and Lenzenweger found that women endorsed a greater number and variety 
of body modifications compared to men in their sample.17 Because of this, it is important 
to make sure that sex is controlled for by attempting to recruit a sample consisting of 
approximately equal numbers of males and females. A second demographic important to 
control for is age, due to its possible effect on impulsivity. To date, some studies have 
illustrated that there appears to be increased impulsiveness in younger adults, with a 
reduction of this impulsivity and a subsequent reduction in suicidal behavior as 
individuals with BPD get older.55-57 Yet despite this evidence, some research refutes this, 
with data suggesting that there is no statistically significant difference in impulsiveness, 
suicidal behavior, or self-harm in younger versus older adults.58 Each of these studies 
divided their participants into either two (younger and older adults),56 three (young, 
middle-aged, and older adults),57,58 or four groups (adolescents, young adults, middle-
aged adults, and old adults).55 Given significant discrepancy in data, this current study 
will control for age by only allowing for the recruitment of participants between the ages 
of 18 and 65.  
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A final possible confounding variable is history of childhood abuse or trauma. In 
a retrospective study looking at individuals with BPD admitted to an inpatient psychiatric 
unit, a significant correlation was made between prolonged childhood sexual abuse and 
rate of engagement in NSSI, number of suicide attempts, cigarette smoking, alcohol use, 
and sexual impulsivity.59 This data suggests that in people with BPD, a history of 
childhood sexual abuse may lead to an increased likelihood of later engaging in self-
injurious or painful behavior. Since this study is looking at painful forms of body 
modification, one could suspect that childhood trauma could be a potential confounding 
variable. In order to assess for history of childhood trauma, the Early Trauma Inventory– 
Self Report-short form (ETISR-SF) will be completed at the baseline visit. Data from this 
questionnaire and any differences in trauma history that exists between treatment groups 
will be considered during data analysis and interpretation.  
2.4 REVIEW OF RELEVANT METHODOLOGY  
2.4.1 Study Design  
2.4.1.1 DBT Program 
Participants enrolled in this study will be randomized to one of three conditions: 
12 weeks of outpatient DBT, pharmacotherapy alone, or non-treatment. While DBT 
programs are traditionally outpatient and one year in duration, inpatient programs of a 
shorter duration have also been found to be effective. Bohus, et al. conducted a pilot 
study in which they established and evaluated the efficacy of a 12-week inpatient DBT 
treatment program.60 Analysis of their data demonstrated that after 12 weeks of inpatient 
DBT, patients demonstrated a decrease in self-injury, dissociation, anxiety, global stress, 
and improvement in depressive symptoms.60  
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These results were further supported by a trial which enrolled female participants 
diagnosed with BPD (who engaged in NSSI or had one suicide attempt within the past 2 
years) into a 12-week inpatient DBT program.61 These researchers compared this 
treatment group to a control group of participants diagnosed with BPD who were on a 
waiting list to enroll in DBT.61 In this trial conducted by Bohus, et al., the inpatient DBT 
program followed DBT guidelines as set forth by Linehan and included the following: 
individual therapy (2 hours/week), group skills training (2 hours/week), group 
psychoeducation (1 hour/week), peer group meetings (2 hours/week), mindfulness group 
(1 hour/week), individual body-oriented therapy (1.5 hour/week), and therapist team 
consultation meetings (2 hours/week).1,61 Results from this study demonstrated that 
following 12 weeks of inpatient DBT, patients demonstrated reductions in self-injury, 
greater clinical improvement, and improvements in “dissociation, depression, anxiety, 
interpersonal functioning, social adjustment, and global psychopathology.”61  
While researchers have demonstrated a benefit from 12 weeks of inpatient DBT in 
people with BPD, researchers are now beginning to evaluate the efficacy of outpatient 
DBT programs of reduced duration.62-64 One such group of researchers were able to 
demonstrate a “partial remission” (as demonstrated by statistically significant 
improvements in the Beck Depression Inventory, Symptom Checklist, and Borderline 
Symptom List 95) in people with BPD following 12 weeks of DBT in a day clinic 
setting.63 A similar study employed a 14-week outpatient DBT program for individuals 
with BPD, and found a significant reduction of the severity of borderline symptoms after 
study completion.62 This research demonstrates that outpatient intensive (12 to 14 weeks) 
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DBT programs can also be successful in improving and managing symptoms in people 
with BPD.  
2.4.1.2 fMRI Procedure 
All participants enrolled in this study will complete two fMRI sessions, one 
session at baseline prior to randomization and the second session after completion of the 
12-week intervention. In a study conducted by Niedtfeld, et al., BPD participants 
receiving DBT treatment, were compared to those receiving treatment as usual and to 
healthy control subjects.52 These participants completed two fMRI sessions (using a 3T 
MRI scanner), one session at baseline and a second session 12 weeks later.52 This study 
was successful in finding significant differences in brain activation in the dlPFC and left 
amygdala, which were no longer present after 12 weeks of treatment with DBT.52  
2.4.1.3 Pain Thresholds 
Quantitative sensory testing (QST) is frequently utilized in order to evaluate an 
individual’s temperature threshold and pain response.65 The method of limits is one 
technique that can be applied and is a standard for conducting QST.66 This method was 
first used by Fruhstorfer, Lindblom, and Schmidt in order to compare “thermal 
sensibility” in subjects with neurological disorders compared to healthy control 
subjects.67 Frushstorfer used a thermostimulator and constant current source in order to 
determine warm, cold, heat pain, and cold pain thresholds in participants.67 To determine 
the warm and cold thresholds, the thermostimulator was first applied to subjects’ skin and 
they were asked to reverse a switch when they felt the stimulator getting warm.67 Once 
they did this, the current would reverse, causing the stimulator to become cool.67 Subjects 
were then advised to reverse the switch a second time once they began to feel the 
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stimulator getting cold.67 This was continued for a total of two minutes, during which 
time the temperatures at which the switch was reversed were recorded.67  
Once the warm and cold thresholds were established, each subject’s cold pain and 
warm pain thresholds were determined. To do so, a baseline temperature of 30°C was 
applied to the subjects’ skin and this temperature was decreased at a rate of either 
1.0°C/second or 1.5°C/second (depending on the skin area).67 Subjects were advised to 
activate the switch when the stimulus was painful, which reversed the current. 
Temperature was then increased at a rate of either 1.0°C/second or 1.5°C/second, and 
subjects were again asked to activate the switch when the stimulus was perceived as 
painful.67 This method was found to be successful in quickly and reliably determining 
temperature thresholds in study subjects. The method of limits has been used to evaluate 
temperature perception at various parts of the body (volar distal forearm, thenar 
eminence, lower medial calf, and lateral dorsal foot).68 Recommendations from current 
research, suggest using a baseline temperature of 32°C and a 1°C/second rate of 
temperature change.68   
Heat pain and cold pain thresholds have been studied in BPD using similar 
methods.52 Like the method established by Fruhstorfer, Lindblom, and Schmidt, one 
recent study conducted by Niedtfeld, et al. delivered temperature stimuli to the skin of 
participants using a Thermal Sensory Analyzer II.52 They utilized a baseline temperature 
of 38°C, which was either increased or decreased at a rate of 2°C/second in order to apply 
three ascending and three descending temperature stimuli, and patients were asked to 
press a button once they perceived the stimulus to be painful.52 Using this information, 
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these researchers were then able to determine an individualized painful stimulus which 
would be administered during each participant’s fMRI scan.52   
2.4.2 Study Setting 
DBT has been found to be an effective treatment regimen for patients with BPD 
in both inpatient and outpatient settings.4,6,7,60-64,69 There does not appear to be data 
demonstrating that either setting is preferred. When administered on an outpatient basis, 
studies have frequently included selection criteria stating that participants must live 
within a certain radius in order to maximize engagement in further outpatient DBT 
sessions and to limit rate of attrition.61  
2.4.3 Selection Criteria 
Participants must meet DSM-V criteria for BPD as outlined in Table 1.53  
Additionally, both the Structured Clinical Interview for DSM-IV Personality Disorders 
(SCID-I and SCID-II)70 and the Diagnostic Interview for Personality Disorders (DIPD) 
BPD questions71 will be utilized to confirm that study participants meet the diagnostic 
criteria for BPD. Participants who meet ≥5/9 of the DIPD criteria will be included. The 
age range of eligible participants is 18-65 years of age. Comparable studies have included 
similar age ranges and typically have an average age of 29-30 years old.31,38,54,72 
Participants that engage in frequent body modification will be selected and 
included in this study. Prior studies looking at self-mutilating behavior and NSSI 
demonstrate a wide variability in what is considered “frequent” or “recent” behavior. In 
one study looking at NSSI in individuals with BPD, participants were required to have a 
history of “at least three incidents of self-mutilating behavior, in the absence of pain, 
within the past 2 years,”31 while a similar study, required participants to have engaged in 
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NSSI at least once within the past month.54 Other comparable studies do not specify that 
its participants needed to engage in a specific number of self-injurious behaviors or NSSI 
in order to be eligible for participation. One of these studies found that there was a range 
from one single episode to up to eight times per month (with an average of 3 times per 
month),38 while another found that its participants “committed NSSI at least once per 
week during the preceding 6 months.”41 In general, when evaluating the severity of a 
disease, clinicians typically rate a patient’s symptoms on a scale of mild, moderate, or 
severe. Yet current research demonstrates that there does not yet exist a standardized 
method for classifying individual’s frequency or recency of NSSI or body modification 
into one of these categories in order to determine severity of behavior (mild, moderate, or 
severe). Because of this, our study will model itself after St. Germain and Hooley54 and 
require that participants have engaged in body modification at least once within the past 
month.  
Each participant’s past medical history will be carefully reviewed to determine 
study eligibility. Exclusion criteria will include the following: history of any serious 
medical or neurological illness, traumatic brain injury, schizophrenia, bipolar (Type I) 
disorder, current Major Depressive Disorder (MDD) within the past 6 months, 
developmental disorders such as Attention Deficit Disorder (ADD) or Attention Deficit 
Hyperactive Disorder (ADHD), chronic pain disorder, peripheral neuropathy, loss of 
consciousness, or a substance use disorder. It is important to control for these diagnoses 
for several reasons as outlined by the DSM-5.53 Additionally, these exclusionary medical 
conditions are those which are widely excluded from previous peer-reviewed articles of 
similar topics and study designs.29,35,39,41,52,72-75 
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Medications are permitted in this study but must not be modified within four 
weeks of screening for study eligibility. Excluded medications include the following: 
chronic NSAID use (daily use for greater than one year), any opioids (within the past 
three months prior to study enrollment), opioid replacement therapy (such as methadone, 
suboxone, buprenorphine, or naltrexone), topiramate, lamotrigine, lithium, 
benzodiazepines, and muscle relaxants. The list of excluded medications and requirement 
for medication stability for four weeks prior to screening is based on the protocols set 
forth by prior peer-reviewed studies of similar study populations and outcomes.38,41,54,72 
2.4.4 Exposure  
This study will randomly assign study participants to one of three treatment 
groups for 12 weeks: DBT, pharmacotherapy alone, and non-treatment (treatment as 
usual). As previously discussed, DBT is the first-line treatment for BPD and seeks to 
teach individuals with BPD improved techniques to manage interpersonal problems.76,77 
Typically, DBT programs are of a 12-month duration, but additional research has 
demonstrated that 12 weeks of either inpatient or outpatient DBT has been effective in 
the management and improvement of BPD symptoms.60-64 Given the substantial data to 
support the utilization of DBT in the treatment of BPD, this will be one treatment group 
within this proposed study.  
A second group of participants within this study will be assigned to 
pharmacotherapy alone. While DBT is the first-line therapy for the treatment of BPD,76  
providers will often utilize pharmacotherapy in order to assist with the management of 
specific symptoms. The APA Practice Guidelines has stated that pharmacotherapy may 
help reduce the severity of specific symptoms in BPD such as affective instability, 
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impulsivity, and self-destructive behavior,76 all of which likely play a role in an 
individual’s engagement in NSSI or body modification. The APA guidelines provide 
recommendations for specific pharmacotherapy options, with the first-line 
pharmacotherapy option being SSRIs such as fluoxetine and sertraline.76 Other second-
line pharmacotherapy options include monoamine oxidase inhibitors (MAOIs) such as 
phenelzine or tranylcypromine and mood stabilizers (lithium, carbamazepine, or 
valproate).76  
The third and final treatment group included in this study will be a non-treatment 
or treatment as usual group. Similar peer-reviewed studies have included non-treatment 
groups, which serve as a control group of participants.7,61 In one study conducted by 
Psieczney and Connor, participants in the treatment as usual group still received clinical 
case management from multidisciplinary case managers.7 This study design allowed for a 
control group, but was ethical in that it still allowed for weekly contact with participants 
and care in the form of “engagement, ongoing assessment, planning, linking with 
community resources, consultation with carers, assistance expanding social networks, 
collaboration with medical staff, advocacy, individual counseling, living skills training, 
psychoeducation and crisis management.”7 Another strategy that has been employed is to 
consider participants on a waitlist for study treatment as control participants, until they 
were able to receive study treatment.61 When an individual was on this waitlist, they were 
not allowed to enroll in DBT programs, but were allowed to engage in “some form of 




The primary outcome of this study will be number of body modifications, as 
determined by the Body Modification Questionnaire (BMQ). This is a 118-item 
questionnaire that was developed by Vizgaitis and Lenzenweger and allows participants 
to provide information on body modifications such as piercings, tattoos, scarifications, 
pubic hair removal, and cosmetic surgery.17 The BMQ will be administered during 
screening (as a condensed version), at baseline, and following 12 weeks of intervention. 
In addition to the BMQ, information pertaining to how frequently and for how long a 
participant has engaged in body modification will be obtained. 
Additionally, this study will have several secondary outcomes including 
temperature threshold and pain response, which will be analyzed using QST delivered 
through a probe administering thermal stimuli to participants during fMRI scans. As 
established by prior studies, participants will receive a customized hot and cold painful 
stimulus through a Thermal Sensory Analyzer II probe.52 With this stimulus, pain 
response, pain thresholds, and pain endurance will be analyzed at baseline and after 12 
weeks of assigned intervention. While these painful stimuli are administered, an fMRI 
scan will be completed at both baseline and after 12 weeks of intervention. This fMRI 
data will be novel in that no fMRI data has yet to be obtained in individuals with BPD 
who engage in frequent body modification. This study will ultimately aim to evaluate if 
like prior studies, there is a significant difference in activity in the dlPFC, posterior 
parietal cortex (PPC), ACC, and amygdala when individuals with BPD are exposed to 
painful stimuli,35 or alternatively, if this pattern of activity somehow differs in individuals 
with BPD who engage in frequent body modification. The activities of these brain 
regions in response to painful stimuli will be re-evaluated following 12 weeks of 
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intervention, to determine if like prior studies, participants enrolled in DBT demonstrate 
changes from baseline patterns of brain activation.52 
This study will also assess childhood trauma using the Early Trauma Inventory– 
Self Report-short form (ETISR-SF),78 which will be administered at baseline. This 
interview consists of 27 items and evaluates physical, emotional or sexual abuse, general 
traumatic experience, and the most serious trauma prior to 18 years old.78 Prior studies 
have demonstrated that increased cases and amount of abuse has a positive correlation 
with number and severity of BPD symptoms.79 Having this baseline information will 
allow for the evaluation and interpretation of any possible differences in childhood abuse 
history that may exist between groups.   
One additional outcome to be assessed at both baseline and following 12 weeks of 
intervention will be the function and awareness of body modification. An interview 
modeled after that designed by Klonsky will be utilized.13 This interview will assess (i) 
history of body modification, (ii) consequences of the body modification, (iii) affect-
states before and after the body modification, and (iv) reason for the body modification.13 
An example of possible options for consequences, affect-states, and reasons provided to 
participants has been provided in Appendix A. This interview will allow for the 
evaluation of how aware participants are about their body modifications, and the 
emotions which they are experiencing prior to, during, and after engaging in the behavior. 
Appendix A: Responses for Interview regarding consequences, reasons, and affect-
states related to body modification 
Consequences Reasons Affect-States 
I experience an adrenaline 
rush 
To express to others how I 
am feeling 
Angry (at others) 
Distracts me from memories To fit in with my peer-group Angry (at self0) 
Marks are left on my skin To let others know what I Sad 
29 
 
am going through 
Family members become 
concerned for me 
To cope with/avoid 
memories of negative 
childhood experiences 
Afraid 
Close friends become 
concerned for me 
To release emotional 
pressure that builds up 
inside of me 
Excited 
  
2.4.6 Sample Size and Statistical Tests 
To determine the appropriate sample size of this study, precedence set forth by 
prior comparable studies, NIH Exploratory/Developmental Research Grant Award (R21) 
monetary allowances, and Cohen’s d effect sizes were all considered. Goodman, et al. 
conducted a similar study in which they evaluated fMRI pre- and post-12-months of DBT 
in individuals not previously receiving treatment.74 These researchers hypothesized that 
participants with BPD would demonstrate statistically significant changes in amygdala 
activation and improved emotion regulation following 12 months of DBT.74 This study 
utilized a sample size of 22 participants (11 controls and 11 participants diagnosed with 
BPD) and found a significant change in amygdala activity over time in the BPD group.74 
While this represents a small sample size, Goodman, et al. were able to demonstrate 
significant between-group differences in a similar population of participants and with 
similar interventions as those set forth by this proposed study.74 
A second study conducted by Niedtfeld, et al. utilized fMRI to assess the changes 
in pain thresholds and appraisal of pain in participants with BPD after completing 12 
weeks of DBT, compared to participants with BPD undergoing treatment as usual and a 
healthy control group.52 This study recruited a total sample size of 66 participants in total 
and hypothesized that pain-mediated affect regulation would normalize, and that pain 
sensitivity would be reduced in participants with BPD following completion of 12 weeks 
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of DBT.52 With this sample size, these researchers were successful in elucidating 
significant differences in amygdala activation and inhibitory coupling of the left 
amygdala and dACC pre- and post-12 weeks of DBT.52 Niedtfeld, et al. acknowledge 
their small sample size and the effects which this had on their study’s statistical power, 
but also comment on the difficulties they faced in recruiting BPD participants that did not 
have prior experience with DBT.52 
 In reviewing the protocols and sample sizes set forth by fMRI studies researching 
similar populations of participants with similar research questions, the sample sizes have 
ranged from 12-93 participants.31,35,52,73-75 While these sample sizes are small and do not 
allow for the detection of a small or medium effect size, it is often challenging for 
researchers to recruit a larger number of participants given the population of desired 
participants and exclusion criteria set forth. This study will calculate its sample size based 
off the guidelines set forth by these previous peer-reviewed and published papers, as well 
as monetary restrictions which come with completing a study under an R21 grant.  
The data collected by this study will be analyzed using IBM Statistical Package 
for the Social Sciences (SPSS) Software version 28, a software program which allows for 
the analysis of research data sets and will allow for the completion of a 3x2 repeated 
measures ANOVA.30,52,73 A univariate repeated-measures ANOVA will allow for the 
evaluation of whether or not there is a statistically significant difference in total body 
modifications (as assessed by the BMQ) amongst treatment groups over the duration of 
the 12-week period.80 While other studies have utilized additional software programs 
such as Statistica,74 SPSS is the statistical software that is most frequently used by 




 This extensive literature review was successful in providing background 
information to support and design the current study. There is a substantial number of 
peer-reviewed articles which provide supporting evidence that individuals with BPD 
engage in body modification. While the underlying etiology, neural mechanisms, and 
effect of DBT on this behavior has not yet been studied, similar studies have been 
conducted looking at NSSI in BPD. These peer-reviewed studies will be utilized as 
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Chapter 3 – Study Methodology 
3.1 STUDY DESIGN 
 The proposed study is a RCT that will be conducted in New Haven, Connecticut 
and which will investigate the effects of randomization to 12 weeks of DBT compared to 
groups randomized to 12 weeks of pharmacotherapy alone or 12 weeks of no treatment, 
on mean number of body modifications, as measured by the BMQ, in patients who have 
engaged in frequent body modification within the past six months and who are not 
currently receiving BPD-directed therapy (either pharmacotherapy or behavioral therapy 
such as DBT). A condensed version of the BMQ will be administered at screening to 
determine possible eligibility, and the full version will be completed at both baseline 
(prior to randomization) and following the completion of 12 weeks of the assigned 
intervention. The full version will be used in order to assess for mean change in the 
number of body modifications. DBT will be administered by one post-doctoral student at 
this site who will have completed formal DBT training and has had experience treating 
patients with BPD. The schedule for DBT will follow that set forth by previous research 
and the current standard. It will consist of weekly skills training groups, weekly hour-
long individual psychotherapy sessions, telephone consultation between sessions as 
needed, and weekly therapist consultation team meetings.  
The participants who are randomized to the pharmacotherapy group will be 
prescribed medication by the site’s PI, Dr. Fineberg, who is a clinical Psychiatrist with 
extensive experience treating patients with BPD. These participants, in addition to those 
randomized to the non-treatment (treatment as usual) group, will be asked to return to the 
study’s lab in New Haven, Connecticut once weekly for an hour-long session during 
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which they will meet with the study coordinator and/or the study PI in order to discuss 
community resources, to address any medical needs or concerns, to evaluate need for 
social support, to provide resources for life skills training, to discuss crisis management, 
and to review psychoeducation resources. All three treatment groups will also have once 
weekly phone calls in order to discuss treatment compliance (if applicable), adverse 
events, medication changes, or health changes.  
The study will also aim to investigate the association between randomization to 
12 weeks of DBT compared to groups randomized to pharmacotherapy or no treatment 
on pain perception, tolerance, and endurance. Quantitative sensory testing (QST) using 
the method of limits will be utilized to determine the cold and warm perception 
thresholds for each participant. The Thermal Sensory Analyzer II will be the thermal 
device used in this study. This probe will be placed over the participant’s left forearm and 
will deliver thermal stimuli. The baseline temperature delivered through the probe will be 
32°C, which will be increased or decreased at a rate of 1°C/second with a minimum 
temperature of 10°C and maximum temperature of 50°C. Each participant will be asked 
to press a button as soon as they perceive the stimulus as either getting warmer or colder, 
and again when they perceive it as becoming painful. The temperature will then be either 
increased or decreased at a rate of 3°C/second in order to return to the baseline 
temperature of 32°C. The painful stimulus will be documented for each individual 
participant, and they will be instructed that they will receive 60% of this level of stimulus 
throughout the fMRI session. Participants will then receive either the baseline 
temperature (32°C) or the individualized painful temperature stimulus throughout the 
fMRI scan. A schedule of events has been outlined in Appendix B and is included below.  
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Appendix B: Schedule of Events 
 
Given the nature of the study design and intervention, both study participants and 
study staff (PI, research assistants, and site’s psychologist who will be administering 
DBT) will be notified of the assigned intervention following random assignment. A 
trained neuroradiologist associated with Yale University will be responsible for analyzing 
the MRI images and the site’s PI will be responsible for interpreting the fMRI data. The 
neuroradiologist will remain blinded to treatment allocation throughout the study. 
Randomization software will be utilized to randomly assign participants amongst the 
three groups (DBT, pharmacotherapy alone, or no treatment) equally. 
3.2 STUDY POPULATION AND SAMPLING 
 This study will enroll individuals with clinically diagnosed BPD who are not 
currently receiving BPD-directed therapy (either pharmacotherapy or behavioral therapy 
such as DBT) and who have engaged in frequent body modifications within the past six 
months. Participants included in this study must be within the ages of 18-65, able to 
speak and write in English as assessed during screening procedures by study staff, able to 
provide informed consent, and able to travel to New Haven, Connecticut for study visits. 
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Participants will be eligible for this study if they are not currently using any medications 
or not currently using any of the medications outlined in the list of “Excluded 
Medications” (Table 2). Participants must meet criteria for BPD as outlined by the DSM-
V diagnostic criteria as assessed using the SCID I, SCID II, and Diagnostic Interview for 
BPD. Participants must demonstrate a significant number of total body modifications in 
their lifetime, with at least one body modification within the past month. Initial 
interviews to assess for eligibility will be completed by study staff and research 
assistants, with final confirmation of eligibility completed by the site’s PI. 
  Participants will be excluded from this study if they are currently receiving BPD-
directed therapy (either pharmacotherapy or behavioral therapy such as DBT). This study 
will allow for a history of participation in behavioral therapy such as DBT. If the 
participant has either in the past or is currently receiving treatment for another psychiatric 
diagnosis, they can still possibly participate in the study given that there have not been 
medication changes within four weeks of screening (a list of included and excluded 
medications is provided in Table 2). Participants with a history of any serious medical or 
neurological illness, chronic pain disorder, schizophrenia, bipolar (Type I) disorder, 
current Major Depressive Disorder (MDD) within the past six months, developmental 
disorders such as Attention Deficit Disorder (ADD) or Attention Deficit Hyperactive 
Disorder (ADHD), peripheral neuropathy, traumatic brain injury, or loss of consciousness 
are not eligible to participate in this study. Participants with a history of a substance use 




Participants that have contraindications to MRI, such as claustrophobia or metal 
implant(s) not MRI compatible, are not able to participate in this study. For those 
participants that are female and of childbearing potential, they will be provided 
information regarding risk of MRI in pregnancy prior to all scans and offered the option 
of a urine pregnancy test before proceeding with the completion of the MRI scans. A list 
of all inclusion and exclusion criteria is provided in Table 2. 
Table 2. Inclusion and Exclusion Criteria 
Inclusion Exclusion 
• Age 18-65 
• Clinical diagnosis of BPD as 
defined by DSM-V criteria. 
• Able to speak and write in 
English. 
• Able to provide informed consent. 
• Able to travel to New Haven, 
Connecticut for study visits. 
• No current BPD-directed 
pharmacotherapy or behavioral 
therapy (such as DBT). 
• Unmedicated patients are eligible 
to participate. Any medication that 
does not belong to the list of 
“excluded medications” are 
deemed acceptable for this study. 
• Currently receiving BPD-directed 
therapy (either pharmacotherapy 
or behavioral therapy such as 
DBT). 
• Contraindications to MRI, such as 
claustrophobia or metal implant(s) 
not MRI compatible. 
• Medical history: any serious 
medical or neurological illness, 
chronic pain disorder, 
schizophrenia, bipolar (Type I) 
disorder, current MDD (no 
episode in the past 6 months), 
developmental disorders (ADD or 
ADHD), peripheral neuropathy, or 
substance use disorder. 
• History of traumatic brain injury 
(TBI) or loss of consciousness. 
• Positive urine toxicology screen 
for drugs of abuse on day of MRI 
scans. 
• Medication change within 4 weeks 
of study screening. 
• Excluded medications: chronic 
NSAID use, opioids, opioid 
replacement therapy (such as 
methadone, suboxone, 
buprenorphine, or naltrexone), 
topiramate, lamotrigine, lithium, 
benzodiazepines, muscle relaxants. 
Chronic NSAID use is defined as 




The inclusion and exclusion criteria set forth aims to recruit a sample which 
controls for possible confounding demographics. If this study is unable to recruit 75% of 
the planned sample in the first year, these criteria will be slightly modified in order to 
maximize study enrollment. One such modification would allow for the recruitment of 
participants with a history of MDD within the past year but not within the past three 
months. The second modification would allow participants to have an outpatient 
prescription for an as needed benzodiazepine, but they would not be permitted to use the 
benzodiazepine within one day of their scheduled fMRI scans.  
3.3 SUBJECT PROTECTION AND CONFIDENTIALITY  
 This study protocol and all recruitment materials will be reviewed and approved 
by the Yale University Human Investigation Committee (HIC). Data for this study will be 
collected by study staff at the Connecticut Mental Health Center (CMHC) and the Yale 
Magnetic Resonance Research Center (MRRC). Study staff and research assistants must 
be added to the Yale HIC approved protocol and will be required to complete HIPAA 
Compliance training before engaging in study-related activity. 
 Each study participant will be assigned a unique study identifier during the phone 
screening and all identifying information will be replaced with this identifier. A paper 
record will be used to connect each participant’s personal identifying information with 
the coded, unique study identifier. This record will be kept in a locked filing cabinet in 
the PI’s locked office, with access granted to only the PI and select members of the 
research team. All study data will be entered into computer files using the participant’s 
unique study identifier, and a paper copy will be printed. This data will be stored in 
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locked cabinets located in the PI’s locked office and in password-protected files through 
a Yale University approved database (Yale Secure Box).  
3.4 STUDY RECRUITMENT 
This study will recruit its participants using Yale HIC approved advertisements 
included in local newspapers, posters throughout New Haven, New Haven bus ads, and 
Facebook ads. The Yale New Haven Hospital Psychiatry Department and CMHC will be 
provided study information and advised that they are able to provide appropriate patients 
with study information and study site contact information. A list of potential participants 
who respond to advertisements and endorse interest in the study will be stored in a secure 
Yale University managed database (Yale Secure Box).  
Study staff and research assistants will contact the individuals listed in the 
database by either telephone or encrypted email in order to schedule a time to or to 
complete a phone screening to assess eligibility. All participants that respond to or 
participate in a phone screening will receive a unique study identifier that will replace all 
personal identifying information. During the phone screen, participants will be assessed 
for study eligibility through a series of questions which assess for all other inclusion and 
exclusion criteria as listed in Table 2. Participants will be screened for BPD specific traits 
using the SCID I, SCID II, and DIPD.  Screening for lifetime and recent (past 6 months) 
engagement in body modification will be done using an abbreviated BMQ. If a 
participant is found to be eligible according to the initial phone screening procedure, they 
will be asked to schedule their baseline visit during which eligibility will be further 
evaluated before proceeding. Each participant will be assessed for peripheral neuropathy 
using a Semmes-Weinstein monofilament at the baseline visit. If a participant meets all 
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inclusion criteria, no exclusion criteria, and the PI deems eligible, then they will be able 
to proceed to randomization. 
3.5 STUDY VARIABLES AND MEASUREMENTS 
 In this RCT, the independent variable or primary intervention is treatment 
assignment. Treatment assignment will be divided such that participants will be randomly 
assigned to one of three groups: DBT, pharmacotherapy alone, and non-treatment. DBT 
is the primary outcome measure, with pharmacotherapy as a comparison group, and the 
non-treatment group as a control. The main outcome or dependent variable will be the 
mean change in body modifications as measured through the BMQ. This main outcome 
variable will be measured as a continuous variable at both baseline and the 12-week 
follow-up visit. In addition to the BMQ, information pertaining to how frequently and for 
how long a participant has engaged in body modifications over their lifetime will be 
obtained at baseline. 
Multiple secondary outcome variables will be the studied as well. The first 
secondary outcome variable will be the change in neural activation in response to painful 
stimuli as assessed by fMRI at two timepoints: baseline and post-intervention (12 weeks). 
An additional secondary outcome will be change in pain perception, threshold, and 
endurance in response to painful stimuli as measured by the Quantitative Sensory Testing 
Task (QST) at two timepoints: baseline and post-intervention (12 weeks). A third 
covariate will be the Early Trauma Inventory–Self Report-short form (ETISR-SF) which 
will be administered at baseline in order to evaluate each participant’s trauma history, as 
this may contribute to study results. Finally, at both baseline and study completion, an 
interview assessing consequence, reason, and emotional affect related to body 
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modification will be conducted. This will allow for a better understanding of each 
participant’s awareness of their engagement in body modification, as well as the 
emotions which they experience before, during, and after this behavior. 
There are several categories of confounding variables which will be accounted for 
and controlled for within this study. The first category of confounding variables consists 
of medical history. This will be controlled for by excluding participants that meet criteria 
for the following: history of any serious medical or neurological illness, traumatic brain 
injury, schizophrenia, bipolar (Type I) disorder, current Major Depressive Disorder 
(MDD) within the past 6 months, developmental disorders such as Attention Deficit 
Disorder (ADD) or Attention Deficit Hyperactive Disorder (ADHD), chronic pain 
disorder, peripheral neuropathy, loss of consciousness, or a substance use disorder.  
A second category of confounding variables consist of medication use. 
Participants on certain medications (chronic NSAID use, opioids, opioid replacement 
therapy, topiramate, lamotrigine, lithium, benzodiazepines, and muscle relaxants) will be 
excluded from this study to limit confounding. Given that participants may have 
concomitant psychiatric conditions that are not exclusionary and for which they may be 
receiving pharmacotherapy, there may be a combination of participants in the DBT group 
who are either taking or not pharmacotherapy that is not DBT-directed therapy. This 
pharmacotherapy may consist of the same medications as those being prescribed in the 
pharmacotherapy group of this study. A third category of confounding variables consist 
of demographics which include age, sex, race, and education.  
3.6 METHODOLOGY CONSIDERATIONS  
3.6.1 Blinding of Intervention  
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 Due to the intervention being utilized in this study, it will not be possible for this 
to be a double-blind RCT. Both participants and investigators (PI, individual 
administering DBT for this protocol, and research assistants) will be notified of each 
participant’s randomization. The site’s neuroradiologist responsible for analyzing the 
fMRI images will remain blinded to intervention allocation throughout the study. 
3.6.2 Blinding of Outcome 
Due to the intervention being utilized in this study, it will not be possible to 
maintain blinding of study outcome. As discussed, personnel responsible for analyzing 
fMRI data will remain blinded to intervention allocation throughout the study. 
3.6.3 Assignment of Intervention 
Participants who provide informed consent at the screening visit and who are 
eligible for this study will be randomized to a treatment arm after the baseline evaluation 
of number of body modifications using the BMQ, pain response, and fMRI. This study 
will use randomization software to randomly assign eligible participants amongst the 
three intervention groups equally. Once baseline measures are completed, a research 
assistant will enter the participant’s unique identifier into the randomization software and 
this will reveal if the participant has been randomized to 12 weeks of DBT, 12 weeks of 
pharmacotherapy alone, or no treatment.  
3.6.4 Adherence 
 Adherence to study intervention will be assessed during weekly telephone 
contacts made by site personnel. The site staff completing this call will be unblinded to 
intervention allocation and will be able to assess for compliance. If a participant is 
assigned to the DBT intervention, they will be asked if they have attended that week’s 
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skills training group, psychotherapy session, and therapist consultation team meeting. If a 
session has been missed, this will be documented along with the reasoning for missing 
the session, and the participant will be instructed of the importance of attending all study 
visits. If the participant is assigned to the pharmacotherapy intervention, they will be 
asked about any missed doses that they may have had that week. They will also be asked 
to count the number of pills that they have remaining of their prescribed medication, this 
number will be documented, and compliance will be calculated. Lastly, if a participant 
has been randomized to the control group with no treatment, these weekly calls will 
solely be to check in regarding an adverse event and/or any medication changes that may 
have been prescribed by an outside provider. During telephone contacts with the DBT 
and pharmacotherapy, groups adverse events and/or medication changes will also be 
assessed.  
3.6.5 Monitoring of Adverse Events 
 This protocol presents minimal risk to participants and adverse events are not 
anticipated. The questionnaires used in this study may cause participants to experience 
feelings of distress due to the questions being posed, but no lasting effects are anticipated. 
MRI is considered a safe procedure given that the guidelines set by the United States 
Food and Drug Administration (FDA) pertaining to magnet strength and exposure will be 
adhered to throughout the study. Additionally, all participants will be provided with an 
MRI safety questionnaire which will assess for the presence of and safety of any metal 
devices, electronic implants, or ferromagnetic materials that may be present on their 
person. All participants will be required to remove metal objects from their pockets and 
any clothing that may contain metal prior to the scan. As an added precaution, each 
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participant will be asked to walk through a metal detector to ensure that all metal objects 
have been removed. All females of child-bearing potential will be offered a urine 
pregnancy test to complete prior to the scan. It is anticipated that some participants may 
begin feeling uncomfortable or anxious during the scan. If this occurs, it is acceptable to 
request discontinuation of the scan. These feelings typically resolve on their own quickly 
with no intervention required.  
Although adverse events are unlikely and not anticipated to occur, study staff will 
contact participants weekly by telephone to complete a health check-in throughout the 
12-week course of the study. Staff will assess for any changes in health or any serious or 
life-threatening and unanticipated events that may have occurred. While not expected, if 
any such event occurs, the PI will be notified of the event as soon as study personnel are 
informed, study activities will be put on hold, and a written report of the incident will be 
provided to the Yale HIC for review.  
3.7 DATA COLLECTION  
Each participant will complete a telephone screening questionnaire with research 
personnel. When contact is made with a participant, they will be assigned a unique study 
identifier which will be associated with a particular participant for the duration of the 
study. The phone screening, baseline, and 12-week follow-up questionnaires will be 
administered through an online survey and analytics tool (Qualtrics) that is approved by 
Yale Web Services, secure, and utilized by Yale School of Medicine. This system allows 
personnel to complete screening documents on behalf of participants, but also allows 
participants to have the ability to complete self-report measures. The data obtained from 
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these surveys will be converted to encrypted computer files and paper versions that will 
be kept locked in filing cabinets and kept confidential.  
The fMRI data obtained through this study will be collected at the Yale MRRC 
(300 Cedar St., New Haven, CT) and stored on their secure servers. A Siemens 3.0 Tesla 
Prisma Fit MRI scanner with a 64-channel head coil for simultaneous multi-slice data 
collection will be used. Imaging sequences collected will include a Localizer, 3D T1 and 
T2 acquisitions (1mm3), single five-minute resting state BOLD scan (multi band 2mm3), 
and the task (temperature stimulation) with BOLD scan. Subjects will respond using a 
2x2 button box synchronized to the task presentation software. Each scan will be labeled 
with the participant’s unique study identifier and no identifiable information. A copy of 
the MRI scan will be converted onto a CD-ROM allowing it to be reviewed by the site’s 
neuroradiologist. Once analyzed, the CD will be stored in locked filing cabinets in the 
PI’s office and will only be accessed by study personnel. The information regarding the 
scan’s results will be shared with only one designated research assistant involved with 
this protocol for analysis. 
3.8 SAMPLE SIZE CALCULATION  
The sample size for this proposed study has been based on both the sample size 
utilized in previous peer-reviewed fMRI studies investigating patients with BPD, but also 
the budget provided by the NIH Exploratory/Developmental Research Grant Award 
(R21). While it is important to utilize studies that have already been reviewed and 
published as a basis for the sample size calculation for this proposed study, it is also 
important to consider the monetary logistics. In order to fund this proposed study, we will 
apply for the NIH Exploratory/Developmental Research Grant Award (R21). The R21 
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grant is intended to encourage exploratory and developmental research by providing 
monetary support for exploratory, novel studies. It provides researchers with eligible 
projects a budget that may not exceed $275,000 over the span of two years, with no more 
than $200,000 allowed to be requested in any single year. This grant does not require any 
preliminary data, although it may be included if available. The budget provided by the 
R21 grant will be used to pay the annual salary for a post-doctoral student that will be 
leading study visits (DBT), data collection, data analysis, and all additional miscellaneous 
study tasks. With an annual salary of $60,000 and the Yale University fringe cost, this 
will be an estimated annual cost of $76,500. We will consider splitting the time of this 
post-doctoral student with another lab in order to help fund their salary. Doing so will 
allow us additional funds in order to pay the salary of the neuroradiolost who will be 
analyzing the study’s fMRI scans. This protocol will also require that we hire a research 
assistant to help with study-related tasks (recruitment, IRB protocol submissions, data 
entry, etc.) three to four days per week, which we estimate to be an annual cost of 
$19,125 when considering an annual salary of $37,500 and a Yale fringe cost of $10,312. 
When considering the annual cost of the salaries for both a post-doctoral student and 
research assistant, we anticipate that we will have an estimated remainder of $83,750 
over the span of two years for study equipment, supplies, and subject compensation. This 
study is a longitudinal fMRI study that will require subjects to undergo two MRI scans 
over the span of 12 weeks, with each scan costing an estimated $500. This study will also 
compensate participants $50 per MRI visit.  
This study will be analyzed using a 3x2 repeated measures ANOVA. The 
guidelines set by Cohen have provided the following benchmarks for effect sizes: small 
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(f=0.1), medium (f=0.25), and large (f=0.4).  G*Power was used to determine sample 
sizes using these effect sizes and a pre-determined power of 0.8 and alpha of 0.05. This 
study would require a sample size of 12 participants to achieve a large effect size, 27 
participants for a medium effect size, and 150 participants for a small effect size given 
the above parameters.  
Given that this is an exploratory and novel project that would likely be funded by 
an R21 grant as described above, the sample sizes provided by the G*Power analysis are 
not achievable through this grant. The sample size proposed for this study will be 45 
participants, who will be evenly divided into the three treatment groups (DBT, 
pharmacotherapy, and no treatment). This sample size is based on the sample sizes 
utilized in similar peer-review projects and is realistic given funding limitations. It is 
hoped that the preliminary data from this pilot study can be used to apply for an R01 
grant which would allow for a larger budget and ultimately a larger sample size.  
3.9 ANALYSIS  
 The data collected by this study will be analyzed using SPSS Software version 28. 
The primary outcome (mean change in body modifications) and secondary outcomes 
(pain perception, threshold, and tolerance) will be evaluated using a 3x2 repeated 
measures ANOVA. The between-subjects factor is the study intervention (DBT, 
pharmacotherapy alone, or non-treatment) and the within-subjects factor is the time point 
that data is obtained (baseline and 12 weeks). These will be analyzed for each of the 
dependent variables (number of body modifications, pain perception, pain threshold, and 
pain tolerance).  
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For image pre-processing, we will convert the DICOM files to .nii format, crop 
the first five runs, and motion correct. Pre-processing steps are done on a Linux platform 
employing in-house code in conjunction with SPM and FSL utilities. Images will then be 
registered to stripped MPRAGE images (using BioImage Suite). All comparisons will be 
checked and edited for motion balance. To test our hypotheses, we will test the effect of 
pain on limbic (amygdala and ACC) and prefrontal (dlPFC and BA8) brain regions given 
the involvement of these areas in emotion processing in BPD.1 These regions of interest 
(ROI) will be defined using automatic segmentation methods, such as FreeSurfer. We 
will use a general linear model (GLM) to test regressors of interest in Matlab. All GLMs 
will be computed at the subject level, with resulting B-weights entered into second level 
analyses (to compute between-group and between-condition comparisons), as in a 
random-effects model. The false discovery rate method will be used to correct for 
multiple comparisons.   
3.10 TIMELINE AND RESOURCES  
 The proposed study will take place over the span of two years as allowed for by 
the R21 grant. If recruitment is delayed due to restrictive inclusion criteria, these criteria 
will be modified as described above. The Yale MRRC located in the Anlyan Center at 
300 Cedar St., New Haven, CT will be utilized in order to acquire and store fMRI data. 
We will rely heavily on our colleagues and local neuroradiologist for the evaluation and 
interpretation of fMRI data. Office space will be provided by the PI of this study (Dr. 
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Chapter 4 – Conclusion 
4.1 Advantages  
BPD has been estimated to effect anywhere from 0.5%-5.9% of the general 
population.1,2 For years, there has existed anecdotal evidence of a connection between 
BPD and increased engagement in both NSSI and body modification.3 It has not been 
until recently that researchers have published data which has formed a quantitative 
connection between severity of BPD and number of body modifications completed.4 One 
major advantage of this study is that it focuses on a topic which, to date, does not have 
robust peer-reviewed literature. While researchers have proposed possible underlying 
neural mechanisms for NSSI in people with BPD and the effects of DBT on this 
behavior, no data has yet been published which studies these concepts as they are related 
to body modification in BPD. This project represents a novel topic in which researchers 
do not yet have much quantitative data or a firm understanding. 
A second advantage of this study is that it is a RCT. RCTs are considered the gold 
standard in evaluating the efficacy of a specific treatment modality. By proposing an 
RCT, this study allows for the equal and random assignment of participants to each 
intervention group in order to avoid any possible or inadvertent biases that may arise with 
alternative study designs.  
4.2 Disadvantages 
While this study certainly has several advantages, disadvantages are present as 
well. One disadvantage of this study is the study’s proposed sample size. According to 
G*Power, this study would require a sample size of 12 participants to achieve a large 
effect size, 27 participants for a medium effect size, and 150 participants for a small 
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effect size. Due to monetary constraints set forth by the R21 grant, which would fund this 
study, a sample size of 45 participants has been proposed. While this is certainly a small 
sample size and does not achieve the statistical power needed to detect small effects, this 
sample size does not vary significantly by the precedent set by previous studies of 
comparable populations5-10 and would allow for medium effects to be detected. 
Depending on the results of this proposed study, future studies may consider recruiting a 
larger population size in order to achieve the desired sample of 150 participants and to 
detect the smallest effects which may be missed in this study.   
A second disadvantage of this study is that there will not be a way to make the 
experiences of each treatment group identical. As discussed, the DBT group will be 
engaged in weekly skills training groups, weekly hour-long individual psychotherapy 
sessions, telephone consultation between sessions as needed, and weekly therapist 
consultation team meetings.11 In comparison, the pharmacotherapy and non-treatment 
groups will only have once weekly hour-long sessions during which they can request 
community or educational resources, address any medical concerns, and discuss crisis 
management techniques. While this will allow for these two groups to have contact with 
study staff throughout their study participation, it will not equate to the amount of time 
that the DBT group will spend engaging with site staff. This should be considered when 
interpreting this study’s results, and future studies may want to consider other methods to 
control for this discrepancy.  
4.3 Clinical Significance 
This study will serve to provide novel, quantitative data on the effects of DBT on 
the engagement in body modification in people with BPD. Additionally, this data will 
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help to develop a better understanding of this behavior’s underlying neural mechanisms, 
may demonstrate that there is utility in the engagement in body modifications (provide 
relief from stressors, improve negative emotions, provide a sense of self, etc.), and will 
likely prompt future research on this topic. With this data, healthcare providers will be 
better able to recognize body modification in their patients and understand how DBT may 
affect their patients’ engagement in this behavior. Additionally, this study’s findings will 
assist providers in being able to better discuss this behavior with their patients and 
provide their patients with more information on why they may be drawn to engage in 
such behavior. Ultimately, this study’s results will not only educate healthcare providers, 
but also people with BPD who engage in frequent body modification. 
4.4 Future Directions 
This proposed research study serves as a foundation for future studies aimed to 
investigate similar populations of patients and ask similar research questions. It may be 
interesting for future studies to delve further into the evaluation of the different types of 
body modifications, in order to evaluate if treatment influences this. For instance, if the 
results from this study do not demonstrate that 12 weeks of DBT result in a statistically 
significant overall reduction in engagement in body modification, it would be interesting 
to evaluate the different types of body modifications that study participants endorsed at 
the end of the 12-week period. Perhaps it is found that there is a significant reduction in 
the number of permanent body modifications, which are focused on in this study 
(piercing, tattooing, cosmetic surgery, etc.), but that there is an increase in non-permanent 
body modifications (hair cutting, hair coloring, or thick make-up application). Such 
results may suggest that treatment with DBT may have an overall effect on reducing 
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painful, permanent behaviors, but that it does not affect engagement in non-painful, non-
permanent body modifications which may serve as a way for people with BPD to obtain a 
sense of self.  
A second consideration for future studies is that many individuals who do not 
meet the diagnostic criteria required for a diagnosis of BPD, also engage in frequent body 
modifications. It may be interesting for future researchers to design a study similar to the 
one proposed, but which also recruits two additional groups of participants: those that do 
not have any underlying psychiatric diagnoses but engage in frequent body modifications 
and those with psychiatric diagnoses other than BPD who engage in frequent body 
modifications. This study would allow for the comparison of these three groups, allowing 
researchers to evaluate any potential differences in baseline demographics, response to 
DBT, pain response, and the underlying neural mechanisms present. This would provide 
researchers and clinicians more information about how and why body modifications may 
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Appendix A: Responses for Interview regarding consequences, reasons, and affect-
states related to body modification 
Consequences Reasons Affect-States 
I experience an adrenaline 
rush 
To express to others how I 
am feeling 
Angry (at others) 
Distracts me from memories To fit in with my peer-group Angry (at self0) 
Marks are left on my skin To let others know what I 
am going through 
Sad 
Family members become 
concerned for me 
To cope with/avoid 
memories of negative 
childhood experiences 
Afraid 
Close friends become 
concerned for me 
To release emotional 
pressure that builds up 






























Table 1. DSM-V Diagnostic Criteria for Borderline Personality Disorder 
A pervasive pattern of instability of interpersonal relationships, self-image, and affects, 
and marked impulsivity beginning by early adulthood and present in a variety of 
contexts, as indicated by five (or more) of the following:  
10. Frantic efforts to avoid real or imagined abandonment. (Note: Do not include 
suicidal or self-mutilating behavior covered in Criterion 5.) 
11. A pattern of unstable and intense interpersonal relationships characterized by 
alternating between extremes of idealization and devaluation.  
12. Identity disturbance: markedly and persistently unstable self-image or sense of 
self. 
13. Impulsivity in at least two areas that are potentially self-damaging (e.g., 
spending, sex, substance misuse, reckless driving, binge eating). (Note: Do not 
include suicidal or self-mutilating behavior covered in Criterion 5.) 
14. Recurrent suicidal behavior, gestures, or threats, or self-mutilating behavior. 
15. Affective instability due to a marked reactivity of mood (e.g., intense episodic 
dysphoria, irritability, or anxiety usually lasting a few hours and only rarely 
more than a few days). 
16. Chronic feelings of emptiness. 
17. Inappropriate, intense anger or difficulty controlling anger (e.g., frequent 
displays of temper, constant anger, recurrent physical fights). 
18. Transient, stress-related paranoid ideation or severe dissociative symptoms. 
Source: Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, 2013, 





Table 2. Inclusion and Exclusion Criteria 
Inclusion Exclusion 
• Age 18-65 
• Clinical diagnosis of BPD as 
defined by DSM-V criteria. 
• Able to speak and write in 
English. 
• Able to provide informed consent. 
• Able to travel to New Haven, 
Connecticut for study visits. 
• No current BPD-directed 
pharmacotherapy or behavioral 
therapy (such as DBT). 
• Unmedicated patients are eligible 
to participate. Any medication that 
does not belong to the list of 
“excluded medications” are 
deemed acceptable for this study. 
• Currently receiving BPD-directed 
therapy (either pharmacotherapy 
or behavioral therapy such as 
DBT). 
• Contraindications to MRI, such as 
claustrophobia or metal implant(s) 
not MRI compatible. 
• Medical history: any serious 
medical or neurological illness, 
chronic pain disorder, 
schizophrenia, bipolar (Type I) 
disorder, current MDD (no 
episode in the past 6 months), 
developmental disorders (ADD or 
ADHD), peripheral neuropathy, or 
substance use disorder. 
• History of traumatic brain injury 
(TBI) or loss of consciousness. 
• Positive urine toxicology screen 
for drugs of abuse on day of MRI 
scans. 
• Medication change within 4 weeks 
of study screening. 
• Excluded medications: chronic 
NSAID use, opioids, opioid 
replacement therapy (such as 
methadone, suboxone, 
buprenorphine, or naltrexone), 
topiramate, lamotrigine, lithium, 
benzodiazepines, muscle relaxants. 
Chronic NSAID use is defined as 
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